Reference Detail


Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at :

Ref Type
Authors H. Pei, S. Parthasarathy, S. Joseph, W.McMillen, X. Xu, S. Castaneda, I. Inigo, K. Britt, B. Anderson, G. Zhao, S. Sawyer, D. Beight, T. Kaoudi, C. Iyer, H. Bian, A. Pappas, D. Surguladze, D. Schaer, K. Benhadji, M. Kalos, Kyla Driscoll
Title LY3200882, a novel, highly selective TGFbetaRI small molecule inhibitor
Abstract Text


  • Case insensitive filtering will display rows where any text in any cell matches the filter term
  • Simple literal full or partial string matches
  • Separate multiple filter terms with a spaces, order doesn't matter (a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page, filtering has no impact on query parameters
  • Use quotes to match a longer phrase which contains spaces "mtor c1483f"


  • Generally, the default sort order for tables is set to be first column ascending, however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column, be sure to set ascending or descending order for a given column, before moving on to the next column.

Molecular Profile Treatment Approach
Gene Name Source Synonyms Protein Domains Gene Description Gene Role
Therapy Name Drugs Efficacy Evidence Clinical Trials
LY3200882 LY3200882 1 1
Drug Name Trade Name Synonyms Drug Classes Drug Description
LY3200882 LY 3200882 TGFBR1 inhibitor 13 LY3200882 is a small molecule that inhibits TGFBR1, potentially resulting in increased anti-tumor immune response and decreased tumor growth (AACR Annual Meeting 2017, Abstract nr 955).
Gene Variant Impact Protein Effect Variant Description Associated with drug Resistance
Molecular Profile Indication/Tumor Type Response Type Therapy Name Approval Status Evidence Type Efficacy Evidence References
Unknown unknown triple-receptor negative breast cancer not applicable LY3200882 Preclinical - Cell line xenograft Actionable In a preclinical study, LY3200882 induced tumor regression in a triple-negative breast cancer cell line xenograft model (AACR Annual Meeting 2017, Abstract nr 955). detail...